Retinoic acid and vitamin E modulate expression and release of CD178 in carcinoma cells: Consequences for induction of apoptosis in CD95-sensitive cells

Experimental Cell Research

Volumn 270, Issue 2, 2001, Pages 248-258

  Salih, Helmut R ^a   Starling, Gary C ^a   Knauff, Markus ^b   Llewellyn, Maj Britt ^a   Davis, Patricia M ^a   Pitts, William J ^a   Aruffo, Alejandro ^a   Kiener, Peter A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

Apoptosis; Carcinoma; FasL; Sheddase; Tumor immunity

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; CD178 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; METALLOPROTEINASE INHIBITOR; RETINOIC ACID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL KILLING; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR IMMUNITY;

EID: 0035500088     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2001.5346     Document Type: Article

References (44)

1. Immunosuppressive factors in human cancer
2. Fas (CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection
3. Melanoma cell expression of Fas (APO-1/CD 95) ligand: Implications for tumor immune escape
4. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
5. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
6. Lymphocyte apoptosis induced by Fas ligand expressing ovarian carcinoma cells: Implications for altered expression of TcR in tumor-associated lymphocytes
7. Tumor counterattack - Concept and reality
8. Antitumor effect of locally produced CD 95 ligand
9. Inhibition of the alloantibody response by CD95 ligand
10. Cutting edge: The tumor counterattack hypothesis revisited: Colon cancer cells do not induce T cell apoptosis via the Fas (CD95, Apo-1) pathway
11. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
12. Identification of amino acid residues important for ligand binding to Fas
13. Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing
14. Stimulation of tyrosine phosphorylation and calcium mobilization by Fcγ receptor cross-linking
15. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS)
16. Human monocytic cells contain high levels of intracellular Fas ligand: Rapid release following cellular activation
17. Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor
18. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of the proapoptotic activity and loss of liver activity
19. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: Modulation by cytokines
20. Induction of apoptosis by IFN-γ in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit
21. Expression of the functional soluble form of human Fas ligand in activated lymphocytes
22. Fas ligand-induced apoptosis as a mechanism of immune privilege
23. Inhibition of death receptor signals by cellular FLIP
24. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
25. Gene transfer of Fas ligand induces tumor regression in vivo
26. Chemotactic activity of soluble Fas ligand against phagocytes
27. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes
28. Regulation of CD 95 (APO-1/Fas) ligand and receptor expression in squamous cell carcinoma by interferon-γ and cisplatin
29. Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture
30. Production of inducible nitric oxide is required for monocytic differentiation of U937 cells induced by vitamin E succinate
31. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: Inhibition of Fas ligand expression by retinoic acid and glucocorticoids
32. 9-Cis retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation
33. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors
34. Regulation of CD 95 (APO-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by interferon-γ and all-trans retinoic acid
35. Down-regulation of Fas ligand by shedding
36. Apoptosis of mouse naïve T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand
37. Differential activity of soluble versus cellular Fas ligand: Regulation by an accessory molecule
38. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells
39. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: Role for Mr 43,000 Fas in VES-triggered apoptosis
40. A selective retinoid with high activity against an androgen resistant prostate cancer cell type
41. KIP1 expression
42. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL
43. Biphasic action of vitamin E on the growth of human oral squamous carcinoma cells
44. Regulation of RARβ expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: Effect on growth inhibition and apoptosis induction